Corrigendum: A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada

V. Hirsh MD, B. Melosky MD, G. Goss MD, D. Morris MD PhD, and W. Morzycki MD

Original Citation


Author Description of the Error

In the article’s Acknowledgments, the company that Anna Christofides represents should have been listed as New Evidence. The corrected acknowledgment follows:

The authors acknowledge medical writing support from Anna Christofides MSc RD of New Evidence; this support was funded by Boehringer Ingelheim Canada.